EUVIMEDObjevte EUVIMED
Open access · CC BY-NC 4.0

Engineered Stable, Antibiotic‐Free, High‐Level Protein Expression in the Probiotic Chassis Escherichia coli Nissle 1917

Halimatun Sakdiah Zainuddin, Sanjeeva Kumar Murali iD, Thomas J Mansell

Biotechnology and Bioengineering · 2026

DOI: 10.1002/bit.70130 ↗

At a glance

Journal article in Biotechnology and Bioengineering, 2026. Written by Halimatun Sakdiah Zainuddin and 2 co-authors. Institution: Department of Chemical and Environmental Engineering, Faculty of Engineering, Universiti Putra Malaysia, Serdang, Malaysia. Major MEDLINE topics: Escherichia coli, Probiotics, Recombinant Proteins, Metabolic Engineering. Cited 8 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NIGMS NIH HHS, NIH HHS, National Institutes of Health.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The application of engineered live biotherapeutic products (LBPs) to secrete small molecules, peptides, or proteins to benefit a human or animal host, relies on heterologous protein expression. Key challenges in this area include expressing protein in a targeted location, the use of antibiotic‐free platforms, and expressing recombinant proteins at titers capable of the desired therapeutic effect. In this study, we sought to engineer the promising candidate probiotic chassis Escherichia coli Nissle 1917 (EcN) as an in situ drug delivery platform. Despite its long history of safe human use and general probiotic characteristics, wild‐type EcN is not optimal for routine protein expression. In this work, we present several approaches to improve protein production in this host. First, we enable stable antibiotic‐free protein expression system via native cryptic plasmids. Next, we integrate the T7 RNA polymerase for high level protein expression. Finally, we knock out OmpT protease activity, enabling expression levels comparable to the industry standard E. coli BL21 (DE3). To demonstrate its application, the above system was adapted to express antimicrobial peptide microcin L (MccL) from EcN, which can potentially reduce gut related pathogens and enhance fitness of the probiotic in the competitive niche of the gut. Overall, this study establishes an antibiotic free and high level protein expression platform in EcN, expandable for in situ delivery of therapeutic proteins.

Subjects

MeSH terms (MEDLINE)

Escherichia coliProbioticsRecombinant ProteinsMetabolic EngineeringDNA-Directed RNA PolymerasesViral Proteins

Author keywords

E. coli Nissle 1917antibiotic free protein expressionanti‐microbial peptideprobioticsprotein expressiontherapeutic protein

Substances

Recombinant Proteinsbacteriophage T7 RNA polymeraseDNA-Directed RNA PolymerasesViral Proteins

Authors and institutions

  • Department of Chemical and Environmental Engineering, Faculty of Engineering, Universiti Putra Malaysia, Serdang, Malaysia.
  • Department of Chemical and Biological Engineering, Iowa State University, Ames, Iowa, USA.

ORCID profiles: Sanjeeva Kumar Murali

Funding

  • NIGMS NIH HHS
  • NIH HHS
  • National Institutes of Health

Cite

APA

Zainuddin, H. S., Murali, S. K., & Mansell, T. J. (2026). Engineered Stable, Antibiotic‐Free, High‐Level Protein Expression in the Probiotic Chassis Escherichia coli Nissle 1917. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.70130

Vancouver

Zainuddin HS, Murali SK, Mansell TJ. Engineered Stable, Antibiotic‐Free, High‐Level Protein Expression in the Probiotic Chassis Escherichia coli Nissle 1917. Biotechnology and Bioengineering. 2026. doi:10.1002/bit.70130

BibTeX
@article{Zainuddin2026,
  author = {Zainuddin, Halimatun Sakdiah and Murali, Sanjeeva Kumar and Mansell, Thomas J},
  title = {Engineered Stable, Antibiotic‐Free, High‐Level Protein Expression in the Probiotic Chassis Escherichia coli Nissle 1917},
  journal = {Biotechnology and Bioengineering},
  year = {2026},
  doi = {10.1002/bit.70130}
}
Start for free →